Interesting, thanks! I wonder if Merck PR’d this news in 2017? I suspect this will be similar.
Why would a big pharma pay $250-300M (for limited to no stake) when they can potentially buy the company at about a billion. That would still be 4 X premium from the current share price. How do they justify that to their board? More importantly, as I mentioned, big pharma wouldn’t allow NWBO to put a statement in 10Q and get ahead of them when the milestone may be another month out. Opens them up to insider trading allegations, competitor disrupting their plans, etc.
By the way, who all were pumping this news that are still around on this platform?